Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Brookmont Capital Management

Share on StockTwits

Brookmont Capital Management lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,136 shares of the biopharmaceutical company’s stock after acquiring an additional 518 shares during the quarter. Gilead Sciences accounts for approximately 1.3% of Brookmont Capital Management’s portfolio, making the stock its 24th largest holding. Brookmont Capital Management’s holdings in Gilead Sciences were worth $1,778,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Malaga Cove Capital LLC increased its stake in shares of Gilead Sciences by 0.6% during the second quarter. Malaga Cove Capital LLC now owns 24,813 shares of the biopharmaceutical company’s stock worth $1,909,000 after acquiring an additional 143 shares during the period. Anderson Fisher LLC boosted its holdings in Gilead Sciences by 0.9% during the second quarter. Anderson Fisher LLC now owns 17,237 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 149 shares in the last quarter. Archford Capital Strategies LLC boosted its holdings in Gilead Sciences by 1.5% during the second quarter. Archford Capital Strategies LLC now owns 9,912 shares of the biopharmaceutical company’s stock worth $763,000 after buying an additional 149 shares in the last quarter. Exchange Capital Management Inc. boosted its holdings in Gilead Sciences by 1.2% during the second quarter. Exchange Capital Management Inc. now owns 12,670 shares of the biopharmaceutical company’s stock worth $975,000 after buying an additional 150 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. boosted its holdings in Gilead Sciences by 66.5% during the second quarter. Global Wealth Management Investment Advisory Inc. now owns 388 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 155 shares in the last quarter. Institutional investors and hedge funds own 77.87% of the company’s stock.

NASDAQ GILD traded down $0.96 during trading hours on Friday, reaching $62.00. 12,307,196 shares of the company traded hands, compared to its average volume of 14,747,112. The company has a 50 day moving average of $64.31 and a two-hundred day moving average of $72.31. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 1.22. Gilead Sciences, Inc. has a 12 month low of $61.65 and a 12 month high of $85.97. The stock has a market capitalization of $77.73 billion, a PE ratio of -258.32, a PEG ratio of 0.74 and a beta of 0.55.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 33.59% and a negative net margin of 1.16%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.24 billion. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.85 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were given a $0.68 dividend. The ex-dividend date of this dividend was Monday, September 14th. This represents a $2.72 dividend on an annualized basis and a dividend yield of 4.39%. Gilead Sciences’s payout ratio is currently 44.30%.

A number of research firms recently commented on GILD. Raymond James reissued a “hold” rating on shares of Gilead Sciences in a report on Monday, September 14th. Robert W. Baird reissued a “hold” rating and set a $76.00 price objective on shares of Gilead Sciences in a report on Monday, June 29th. Credit Suisse Group decreased their price objective on shares of Gilead Sciences from $75.00 to $73.00 and set a “neutral” rating on the stock in a report on Friday, July 31st. Oppenheimer boosted their price objective on shares of Gilead Sciences from $90.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Finally, Piper Sandler decreased their price objective on shares of Gilead Sciences from $85.00 to $83.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have assigned a buy rating to the company. Gilead Sciences has a consensus rating of “Hold” and an average target price of $78.93.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: G-20

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply